FDA okays MTI's (Micro Therapeutics) Onyx brain aneurysm trial:
This article was originally published in Clinica
Executive Summary
The US FDA has given Micro Therapeutics (MTI) the go-ahead to begin a 138-patient pivotal trial of its Onyx liquid embolic system for the treatment of brain aneurysms. The product, which is already CE-marked for sale in Europe (see Clinica no 934, p 17), will be tested in 15 US sites. The Irvine, California company says it expects to file a PMA application with the FDA in the second half of 2002.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.